RecallHawk
Class III Recall

Digoxin Tablets, USP 62.5 mcg (0.0625 mg), 100-count bottles, Rx Only, Manufactured by: Novitium Pharma LLC, 70 Lake Dri

Novitium Pharma LLC

Summary

The FDA issued a Class III for Digoxin Tablets, USP 62.5 mcg (0.0625 mg), 100-count bottles, Rx Only, Manufactu by Novitium Pharma LLC. Reason: Failed Impurities/Degradation Specifications.

Details

Source

Drug Recall

External ID

D-0443-2024

Action Date

2024-04-24

Status

Terminated

Category

drug

Product Description

Digoxin Tablets, USP 62.5 mcg (0.0625 mg), 100-count bottles, Rx Only, Manufactured by: Novitium Pharma LLC, 70 Lake Drive, East Windsor, New Jersey 08520, NDC 70954-200-10

Lot/Code Info: Lot M23011A; Exp. 12/2024

Quantity Affected: 1,003 bottles

Reason for Recall

Failed Impurities/Degradation Specifications

Distribution

U.S. Nationwide

Type: Voluntary: Firm initiated

Recall Initiated: 2024-03-25

Company

Novitium Pharma LLC

East Windsor, NJ

Context & Analysis

This is a Class III recall. Class III recalls involve products unlikely to cause adverse health consequences, but that violate FDA regulations.

This was one of 26 drug recalls issued in the same week, part of 267 drug-related FDA actions this month.

Novitium Pharma LLC has 2 FDA actions in our database, including 2 recalls.

Frequently Asked Questions

What is a Class III recall?

A Class III recall involves products that are unlikely to cause adverse health effects but violate FDA labeling or manufacturing regulations.

What should I do if I have this product?

Stop using the product. Check the product against the specific lot numbers or identifiers listed in the recall. Contact the manufacturer (Novitium Pharma LLC) or your retailer for a refund or replacement. If you experienced adverse effects, report them to the FDA via MedWatch.

How often does Novitium Pharma LLC have FDA actions?

Novitium Pharma LLC has 2 FDA actions in our database, including 2 recalls and 0 device clearances.

Where can I find the official FDA record?

The official record is available on FDA.gov. Search for "D-0443-2024" on FDA.gov for the full record. You can also use the openFDA API to query this record programmatically.

Want to know the moment something like this happens?

Get alerts for drug

Related Actions